Cormedix Inc
19KA
Company Profile
Business description
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
Contact
300 Connell Drive
Suite 4200
Berkeley HeightsNJ07922
USAT: +1 908 517-9500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
82
Stocks News & Analysis
stocks
3 "buy the dip" candidates with wide moats
Share price pullbacks can present an opportunity to buy high quality companies at attractive prices.
stocks
Undervalued ASX share hampered by delays in foreign expansion
A near monopoly in Australia pushes this company into global markets but progress has been slow.
stocks
Ask the analyst: Why has MinRes fallen so far?
Mineral Resources shares are down almost 50% year to date. Mark Taylor weighs in on some of the reasons why.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,515.20 | 3.70 | -0.04% |
| CAC 40 | 7,226.98 | 199.90 | -2.69% |
| DAX 40 | 19,033.64 | 414.96 | -2.13% |
| Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
| FTSE 100 | 8,025.77 | 99.42 | -1.22% |
| HKSE | 19,846.88 | 580.05 | -2.84% |
| NASDAQ | 19,281.40 | 17.36 | -0.09% |
| Nikkei 225 | 39,376.09 | 157.23 | -0.40% |
| NZX 50 Index | 12,660.11 | 89.25 | -0.70% |
| S&P 500 | 5,983.99 | 17.36 | -0.29% |
| S&P/ASX 200 | 8,255.60 | 10.60 | -0.13% |
| SSE Composite Index | 3,421.97 | 48.10 | -1.39% |